Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Randomised, Parallel Group, Multicentre, Non-inferiority Study to Compare ZOLADEX 10.8 mg With ZOLADEX 3.6 mg in Chinese Pre-menopausal Patients With Estrogen Receptor-Positive and HER2 Negative Early Breast Cancer

NCT03658213 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03658213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03658213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Randomised, Parallel Group, Multicentre, Non-inferiority Study to Compare ZOLADEX 10.8 mg With ZOLADEX 3.6 mg in Chinese Pre-menopausal Patients With Estrogen Receptor-Positive and HER2 Negative Early Breast Cancer
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Withdrawn
Start date
March 31, 2020
Completion date
November 4, 2021
Enrollment
0 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer